SINGAPORE, 9 September 2026 – ChemT Biotechnology has been selected to participate in TechCrunch Startup Battlefield 200 at TechCrunch Disrupt 2026.

Selected from thousands of applicants worldwide, ChemT will be one of only 200 startups exhibiting at the event, which will take place from 13–15 October 2026 at Moscone West in San Francisco.

ChemT is developing CelMo™, an AI-powered Virtual Cell platform that makes cell behaviour more predictable and controllable. By combining AI, biological data and experimental validation, the platform helps identify actionable biological targets and supports the development of small-molecule interventions to improve biologics manufacturing.

The selection marks an important milestone for ChemT and provides an opportunity to present its work to investors, technology leaders and prospective industry partners from around the world. The team looks forward to sharing its progress and contributing to conversations on the future of AI-enabled biotechnology and biomanufacturing.

TechCrunch Disrupt brings together founders, investors and technology leaders, while Startup Battlefield 200 showcases emerging companies across biotechnology, healthcare, enterprise technology, sustainability and other industries.

Join ChemT at TechCrunch Disrupt 2026 and receive 20% off passes here:https://bit.ly/4bfOmvt

For more information, please contact corporate@chemtbio.com.